SCHEMBL4678048

SCHEMBL4678048

O=C(O)C(O)=CC(=O)c1cocc1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP9 P14780 1/20 0.38
MMP12 P39900 1/20 0.38
MMP13 P45452 1/20 0.38
MMP14 P50281 1/20 0.38
PTGS2 P35354 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
AKR1C3 P42330 1/20 0.36
CYP2D6 P10635 1/20 0.35
IKBKB O14920 1/20 0.35
HSD11B1 P28845 1/20 0.34
HTR2A P28223 3/20 0.34
HTR2C P28335 3/20 0.34
KCNH2 Q12809 2/20 0.34
KDM4E B2RXH2 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678047 1.00 MMP1 (0.38) MMP1MMP2MMP3MMP9MMP12
SCHEMBL4677099 0.88 NPSR1 (0.37) MMP1MMP2MMP3MMP9MMP12
SCHEMBL4677102 0.88 NPSR1 (0.37) MMP1MMP2MMP3MMP9MMP12
SCHEMBL4674107 0.87 ALDH1A1 (0.39) AKR1C2AKR1C1AKR1C3KDM4EMAPT
SCHEMBL4674114 0.87 ALDH1A1 (0.39) AKR1C2AKR1C1AKR1C3KDM4EMAPT
SCHEMBL4672206 0.80 MMP1 (0.39) MMP1MMP2MMP3MMP9MMP12
SCHEMBL4672202 0.80 MMP1 (0.39) MMP1MMP2MMP3MMP9MMP12
SCHEMBL4672643 0.79 MMP1 (0.38) MMP1MMP2MMP3MMP9MMP12
SCHEMBL4672646 0.79 MMP1 (0.38) MMP1MMP2MMP3MMP9MMP12
SCHEMBL4671304 0.77 PTGS2 (0.36) MMP1MMP2MMP3MMP9MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MMP1 1483/4885MMP2 1886/4885MMP3 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.